Pelthos Therapeutics Files 8-K for Reg FD Disclosure

TL;DR

Pelthos Therapeutics (PLTH) filed an 8-K on Sep 3 for events on Sep 2. Standard disclosure filing.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is primarily for Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, formerly known as Channel Therapeutics Corp and Chromocell Therapeutics Corp, is incorporated in Nevada and headquartered in Durham, NC.

Why It Matters

This 8-K filing indicates important disclosures or events have occurred that are relevant to investors, requiring immediate reporting to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for disclosure and exhibits, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Pelthos Therapeutics Inc. (company) — Registrant
• Channel Therapeutics Corp (company) — Former Company Name
• Chromocell Therapeutics Corp (company) — Former Company Name
• September 2, 2025 (date) — Earliest event reported
• September 3, 2025 (date) — Filing Date
• Durham, NC (location) — Principal Executive Office

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share PTHS The NYSE American LL

Filing Documents

• g084940_8-k.htm (8-K) — 27KB
• g084940_ex99-1.htm (EX-99.1) — 34KB
• g084940_ex99-2.htm (EX-99.2) — 7KB
• img001_v1.jpg (GRAPHIC) — 4KB
• img002_v1.jpg (GRAPHIC) — 69KB
• img003_v1.jpg (GRAPHIC) — 183KB
• img004_v1.jpg (GRAPHIC) — 717KB
• img005_v1.jpg (GRAPHIC) — 142KB
• img006_v1.jpg (GRAPHIC) — 78KB
• img007_v1.jpg (GRAPHIC) — 48KB
• img008_v1.jpg (GRAPHIC) — 146KB
• img009_v1.jpg (GRAPHIC) — 122KB
• img010_v1.jpg (GRAPHIC) — 142KB
• img011_v1.jpg (GRAPHIC) — 100KB
• img012_v1.jpg (GRAPHIC) — 48KB
• img013_v1.jpg (GRAPHIC) — 650KB
• img014_v1.jpg (GRAPHIC) — 104KB
• img015_v1.jpg (GRAPHIC) — 121KB
• img016_v1.jpg (GRAPHIC) — 85KB
• img017_v1.jpg (GRAPHIC) — 52KB
• img018_v1.jpg (GRAPHIC) — 109KB
• img019_v1.jpg (GRAPHIC) — 104KB
• img020_v1.jpg (GRAPHIC) — 95KB
• img021_v1.jpg (GRAPHIC) — 146KB
• img022_v1.jpg (GRAPHIC) — 66KB
• 0001753926-25-001425.txt ( ) — 4833KB
• pths-20250902.xsd (EX-101.SCH) — 3KB
• pths-20250902_lab.xml (EX-101.LAB) — 33KB
• pths-20250902_pre.xml (EX-101.PRE) — 22KB
• g084940_8-k_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 2, 2025, Pelthos Therapeutics Inc. (the "Company") issued a press release announcing that its Chief Executive Officer, Scott Plesha, and Chief Financial Officer, Francis Knuettel II, will present at the Wells Fargo 2025 Healthcare Conference in Boston, Massachusetts. Management's presentation will take place on Wednesday, September 3, 2025 at 1:30 p.m. Eastern Time. A webcast of the presentation will be available on the Events and Presentations pages of the Company's website at https://pelthos.com. Archived replays will be available for 90 days following the conference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. At the conference, the Company will provide an update on its product pipeline and discuss recent business developments, including its commercial launch of ZELSUVMI TM . The presentation materials furnished herewith as Exhibit 99.2 (the "Presentation Materials") will be used in connection with such presentation, are incorporated into this Item 7.01 by reference and will be posted on the Company's website at https://pelthos.com. Information contained on the Company's website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, which are incorporated into this Item 7.01 by reference, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. The information set forth in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be dee

Forward-Looking Statements

Forward-Looking Statements Exhibit 99.2 attached hereto contains forward-looking All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) the success of the launch for ZELSUVMI, (ii) the Company's ability to develop its pipeline, (iii) the Company's ability to protect its intellectual property and to enforce its intellectual property rights, and (iv) the Company's ability to execute its development strategy and sustain its competitive position. These statements are not guarantees of future performance and are to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company's Common Stock will be indicative of the combined company's value or that the combined company's Common Stock will become an attractive investment in the future; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulator

01. Financial Statements and

Item 9.01. Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated September 2, 2025. 99.2 Pelthos Therapeutics Inc. Q3 2025 Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2025 Pelthos Therapeutics Inc. By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR